686 related articles for article (PubMed ID: 31171315)
1. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
So A; Inman RD
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
Braun J; Kiltz U; Heldmann F; Baraliakos X
Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
[TBL] [Abstract][Full Text] [Related]
6. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
7. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
8. Intra-articular injections of biological disease-modifying anti-rheumatic drugs in inflammatory arthropathies: An up-to-date narrative review.
Al Khayyat SG; Conticini E; Falsetti P; Fogliame G; Gentileschi S; Baldi C; Bardelli M; Migliore A; Cantarini L; Frediani B
Joint Bone Spine; 2023 Dec; 90(6):105598. PubMed ID: 37271277
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatment options for spondyloarthritis.
Torgutalp M; Poddubnyy D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
[TBL] [Abstract][Full Text] [Related]
10. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
[No Abstract] [Full Text] [Related]
11. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
[TBL] [Abstract][Full Text] [Related]
12. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
[TBL] [Abstract][Full Text] [Related]
14. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
15. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
16. The use of biologics for uveitis associated with spondyloarthritis.
Arepalli S; Rosenbaum JT
Curr Opin Rheumatol; 2019 Jul; 31(4):349-354. PubMed ID: 31107288
[TBL] [Abstract][Full Text] [Related]
17. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
18. Drug therapy in juvenile spondyloarthritis.
Srinivasalu H; Simpson J; Stoll ML
Curr Opin Rheumatol; 2024 Jul; 36(4):295-301. PubMed ID: 38639758
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
Lund Hansen R; Schoedt Jørgensen T; Dreyer L; Hetland ML; Glintborg B; Askling J; Di Giuseppe D; Jacobsson LTH; Wallman JK; Nordstrom D; Aaltonen K; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Love TJ; Kristensen LE
Rheumatology (Oxford); 2021 Jan; 60(1):140-146. PubMed ID: 32591790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
